Pacific Biosciences (PACB) investor relations material

Financial performance and business highlights

• Achieved $39 million in Q2 revenue, with strong consumables growth and 67% increase in clinical business year-over-year.

• Major fleet expansions included two large deals with existing customers and a significant new population genomics initiative, shipping five Revio instruments.

• SPRQ-Nx chemistry launched in May, offering lower ASP and multi-use capability, impacting consumables revenue as customers transition and deplete old inventory.

• Guidance revised downward by $10 million to $160 million midpoint, reflecting slower SPRQ-Nx adoption and tempered expectations for Vega demand.

• Targeted reduction in force focused on marketing and management layers, expected to reduce expenses by $15–20 million and further $30–40 million in 2027 as R&D spend winds down.

Strategic initiatives and operational changes

• Completed CEO transition to Mark Van Oene, emphasizing clinical market expansion and replicating EMEA successes in the U.S. and Asia Pacific.

• Marketing team restructured to focus on clinical, joining the commercial team for unified execution.

• R&D prioritized optimizing GPU and memory usage to mitigate rising compute costs, with improvements expected by 2027.

• Next-generation ultra-high throughput instrument designed for compute efficiency and customer flexibility, with launch targeted for late 2027.

• Vega platform continues to introduce new customers to long-read sequencing, with SPRQ-Nx chemistry for Vega launching in August to expand use cases.

Market trends and growth outlook

• Large-scale population genomics and clinical projects enabled by SPRQ-Nx are expected to drive meaningful revenue starting in 2027.

• Clinical consumables now represent mid-teens percent of total, with robust growth in EMEA due to favorable reimbursement and hospital fit.

• U.S. clinical market growth depends on higher throughput instruments and improved reimbursement; commercial labs are ramping up whole-genome sequencing.

• Increasing demand for high-quality, multi-omic data is driving competitive wins, especially for AI-powered research and clinical discovery.

• Company aims for cash flow positivity in 2028, contingent on successful product launches, compute cost management, and SPRQ-Nx adoption, targeting gross margins near 50%.